E7 TCR-T / Rutgers University - LARVOL DELTA

Rutgers and Iovance Assess E7 TCR T-Cell Therapy in Phase 1/2 Trial for HPV-Associated Tumors (CGTLive) - "The trial, which was launched on August 11, 2025, has an estimated completion date of October 1, 2026...The trial is expected to enroll 15 participants in total...The trial’s primary end point is feasibility as assessed by the proportion of patients who finish treatment without experiencing an event fitting criteria for failure of feasibility, as of 6 weeks post-treatment....According to Rutgers, the E7 TCR-T cell therapy project has funding from the National Cancer Institute equaling $627,893.00 for 2025. The budget start date was August 1, 2025 and the budget end date is July 31, 2026."

Financing • Trial completion date • Trial status • Anal Squamous Cell Carcinoma • Cervical Cancer • Oropharyngeal Cancer • Penile Cancer • Penile Squamous Cell Carcinoma • Vaginal Cancer • Vulvar Cancer • Vulvar Squamous Cell Carcinoma

Liquid biopsy detects treatment resistance to T cell receptor (TCR)-T cell therapy (SITC 2025) - P1/2 | "Practical limitations of tumor biopsy acquisition pose a challenge to studying the frequency and timing of these resistance mechanisms.5 6 Conversely, liquid biopsy offers a minimally invasive and easily repeatable method for real-time monitoring of tumors difficult or inaccessible to biopsy.7 8 This study aimed to determine if HLA-A*02:01 damaging mutations previously identified in tumor biopsies from 2 patients treated in a phase I trial of E7 TCR-T cell therapy for HPV-associated cancers could also be detected with liquid biopsy.3Methods Archived plasma specimens collected before and after treatment from each of the 2 patients (Patients 4 and 5) were studied. This method holds promise for prospectively predicting response and monitoring for the development of resistance to TCR-based therapeutics.Ethics Approval The trial was registered on clinicaltrials.gov, trial number NCT02858310. This study was approved by the NIH IRB; approval number 16C0154."

Biopsy • IO biomarker • Liquid biopsy • Melanoma • Oncology • Sarcoma • Solid Tumor • Synovial Sarcoma • HLA-A